Order Article Reprints

Alonso JM, Escobar-Peso A, Palomino-Antolín A, Diez-Iriepa D, Chioua M, Martínez-Alonso E, Iriepa I, Egea J, Alcázar A, Marco-Contelles J. Privileged Quinolylnitrones for the Combined Therapy of Ischemic Stroke and Alzheimer’s Disease. Pharmaceuticals. 2021; 14(9):861. https://doi.org/10.3390/ph14090861

Alonso, José M., Alejandro Escobar-Peso, Alejandra Palomino-Antolín, Daniel Diez-Iriepa, Mourad Chioua, Emma Martínez-Alonso, Isabel Iriepa, Javier Egea, Alberto Alcázar, and José Marco-Contelles. 2021. "Privileged Quinolylnitrones for the Combined Therapy of Ischemic Stroke and Alzheimer’s Disease" Pharmaceuticals 14, no. 9: 861. https://doi.org/10.3390/ph14090861

Alonso, J. M., Escobar-Peso, A., Palomino-Antolín, A., Diez-Iriepa, D., Chioua, M., Martínez-Alonso, E., Iriepa, I., Egea, J., Alcázar, A., & Marco-Contelles, J. (2021). Privileged Quinolylnitrones for the Combined Therapy of Ischemic Stroke and Alzheimer’s Disease. Pharmaceuticals, 14(9), 861. https://doi.org/10.3390/ph14090861